公开(公告)号：WO2007067808A2

公开(公告)日：2007-06-14

申请号：PCT/US2006047175

申请日：2006-12-08

Applicant: NMK RES LLC ,  KARP NELSON M

Inventor： KARP NELSON M

IPC: A61K39/12 ,  C12N7/00

CPC classification number: A61K39/21 ,  A61K39/12 ,  C12N2740/16034

Abstract: A conditionally live virion and method for making the same whereby the viral DNA or RNA is modified so that the virion is incapable of replication unless a protein supplement is added to the expression system. The expression system is either a traditional cell culture or cell free expression system suitable for self assembly of viral particles. Both expression systems require the addition of viral proteins either for replication or assembly of the replication incompetent virion. The conditionally live viron is then used for creating a vaccine with three fold . immunogenic properties that are elicited by 1) the whole intact replication incompetent virus; 2) the conditionally live virion temporally resuscitated by addition of protein supplements; and 3) the protein supplement itself acting as a subunit vaccine.

Abstract translation: 一种有条件的活的病毒粒子和制备方法，由此病毒DNA或RNA被修饰，使得病毒粒子不能复制，除非蛋白质补充物被添加到表达系统中。 表达系统是适合于病毒颗粒自组装的传统细胞培养物或无细胞表达系统。 两种表达系统都需要添加病毒蛋白，用于复制或组装复制无能力病毒粒子。 然后将有条件的活Vero用于创建三倍的疫苗。 引发的免疫原性1）整个完整复制无能病毒; 2）通过添加蛋白质补充剂暂时复苏的有条件的活病毒体; 和3）蛋白质补充剂本身作为亚单位疫苗。

公开(公告)号：WO2005040353A3

公开(公告)日：2005-12-29

申请号：PCT/US2004035316

申请日：2004-10-25

Applicant: NMK RES LLC

Inventor： KARP NELSON M

IPC: A61K9/00 ,  A61K39/00 ,  A61K39/02 ,  A61K39/12 ,  A61K39/21 ,  A61K47/12 ,  C07K14/16 ,  C12N7/06 ,  C12Q1/70 ,  C12N7/00 ,  C12P21/04

CPC classification number: C12N7/00 ,  A61K9/0014 ,  A61K9/0019 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K47/12 ,  A61K2039/523 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55583 ,  A61K2039/55594 ,  A61K2039/6018 ,  C07K14/005 ,  C12N2710/16243 ,  C12N2740/16034 ,  C12N2740/16063 ,  C12N2740/16122 ,  C12N2740/16222

Abstract: An antigenic and immunogenic composition of predetermined inactivated strains of human immunodeficiency virus (HIV) is disclosed. Inactivation is through psoralen and ultraviolet radiation; the composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H. Determination of strains for inactivation may be though immunotherapeutic genotyping or probabilistic assessment of risk of exposure.

Abstract translation: 公开了预定的人类免疫缺陷病毒（HIV）灭活菌株的抗原和免疫原性组合物。 灭活是通过补骨脂和紫外线辐射; 通过去除干扰免疫应答的HIV的结构特征，使组合变得更有效。 特别地，除去唾液酸以增强组合物的免疫识别并损害补体因子H结合。 CD55和CD59也被去除以防止补体因子H的结合。通过免疫治疗基因分型或暴露风险的概率评估来确定灭活菌株。

公开(公告)号：WO2005040352A3

公开(公告)日：2005-12-29

申请号：PCT/US2004035315

申请日：2004-10-25

Applicant: NMK RES LLC

Inventor： KARP NELSON M

IPC: A61K9/00 ,  A61K39/00 ,  A61K39/02 ,  A61K39/12 ,  A61K39/21 ,  A61K47/12 ,  C07K14/16 ,  C12N7/06 ,  C12Q1/70 ,  C12N7/00

CPC classification number: C12N7/00 ,  A61K9/0014 ,  A61K9/0019 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K47/12 ,  A61K2039/523 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55583 ,  A61K2039/55594 ,  A61K2039/6018 ,  C07K14/005 ,  C12N2710/16243 ,  C12N2740/16034 ,  C12N2740/16063 ,  C12N2740/16122 ,  C12N2740/16222

Abstract: An immunogenic composition able to provide an immune response to Human Complement Factor H binding on one or more HIV glycoproteins is disclosed, which is characterized by at least one binding site epitope of the glycoproteins. Such immunogenic composition wherein the glycoprotein comprises gp120, gp4l, or both glycoproteins gp120 and gp4l is hereby disclosed. Sialic acid is removed to enhance immune recognition of the composition and to impair Factor H binding. A medication having an inhibitive action on autoimmune response by specific inhibition of the cleavage of C3b by Factor H into inactive cell fragments.

Abstract translation: 公开了能够提供对一种或多种HIV糖蛋白的人补体因子H结合的免疫应答的免疫原性组合物，其特征在于糖蛋白的至少一个结合位点表位。 特此公开了其中糖蛋白包含gp120，gp4l或两种糖蛋白gp120和gp4l的这种免疫原性组合物。 除去唾液酸以增强组合物的免疫识别并损害因子H结合。 通过特异性抑制因子H将C3b切割成无活性细胞片段，对自身免疫应答具有抑制作用的药物。

公开(公告)号：WO2005040349A3

公开(公告)日：2006-04-27

申请号：PCT/US2004035210

申请日：2004-10-25

Applicant: NMK RES LLC

Inventor： KARP NELSON M

IPC: A61K39/00 ,  A61K9/00 ,  A61K39/02 ,  A61K39/12 ,  A61K39/21 ,  A61K47/12 ,  C07K14/16 ,  C12N7/00 ,  C12N7/06 ,  C12Q1/70

CPC classification number: C12N7/00 ,  A61K9/0014 ,  A61K9/0019 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K47/12 ,  A61K2039/523 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55583 ,  A61K2039/55594 ,  A61K2039/6018 ,  C07K14/005 ,  C12N2710/16243 ,  C12N2740/16034 ,  C12N2740/16063 ,  C12N2740/16122 ,  C12N2740/16222

Abstract: The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one binding site of Cyclophilin A on the HIV capsid protein. The present invention contemplates three categories of embodiments: protein or protein fragments, messenger RNA, or DNA/RNA. DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.

Abstract translation: 本发明涉及免疫原性组合物。 更具体地，本发明是针对HIV衣壳蛋白上的至少一个亲环蛋白A的结合位点引发免疫应答的组合物。 本发明考虑了三类实施方案：蛋白质或蛋白质片段，信使RNA或DNA / RNA。 DNA / RNA组合物可以是裸体或重组体。 本发明进一步考虑了与各种免疫兴奋剂的用途。

公开(公告)号：WO2005039501A3

公开(公告)日：2005-12-15

申请号：PCT/US2004035317

申请日：2004-10-25

Applicant: NMK RES LLC

Inventor： KARP NELSON M

IPC: A61K9/00 ,  A61K39/00 ,  A61K39/02 ,  A61K39/12 ,  A61K39/21 ,  A61K47/12 ,  C07K14/16 ,  C12N7/06 ,  C12Q1/70 ,  C12N7/00 ,  C12N7/01 ,  C12P21/04

CPC classification number: C12N7/00 ,  A61K9/0014 ,  A61K9/0019 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K47/12 ,  A61K2039/523 ,  A61K2039/5252 ,  A61K2039/5256 ,  A61K2039/5258 ,  A61K2039/53 ,  A61K2039/55511 ,  A61K2039/55583 ,  A61K2039/55594 ,  A61K2039/6018 ,  C07K14/005 ,  C12N2710/16243 ,  C12N2740/16034 ,  C12N2740/16063 ,  C12N2740/16122 ,  C12N2740/16222

Abstract: The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to HIV fusion protein. The present invention contemplates three categories of embodiments: protein or protein fragments, messenger RNA, or DNA/RNA. DNA/RNA composition may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.

Abstract translation: 本发明涉及免疫原性组合物。 更具体地，本发明是旨在引发对HIV融合蛋白的免疫应答的组合物。 本发明考虑了三类实施方案：蛋白质或蛋白质片段，信使RNA或DNA / RNA。 DNA / RNA组合物可以是裸体或重组体。 本发明进一步考虑了与各种免疫兴奋剂的用途。